Malnutrition is one of the main burdens of disease in cystic fibrosis (CF) along with lung disease. Data from the most recent Cystic Fibrosis Foundation registry report show the prevalence of malnutrition is decreasing in the CF population primarily from interventions focusing on preventing malnutrition. Despite success of interventions and decreased prevalence of malnutrition in this population, prevention of malnutrition in CF patients remains a dilemma that must be managed throughout the life cycle. The pathogenesis of malnutrition in CF can be further categorized into 3 main areas: increased energy losses, increased energy needs, and inadequate calorie intake. The purpose of this review is to further explore the causes of malnutrition and explain current research to prevent malnutrition in the CF population.
Cystic Fibrosis Foundation Patient Registry. Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation; 2011.
2.
CorkinsMR. The A.S.P.E.N. Pediatric Nutrition Support Core Curriculum. Silver Spring, MD: American Society for Parenteral and Enteral Nutrition; 2010.
3.
CoreyMMcLaughlinFJWilliamsMLevisonH. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol. 1988;41(6):583-591.
4.
StallingsVAStarkLJRobinsonKAFeranchakAPQuintonH. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc. 2008;108:832-839.
5.
BorowitzDBakerRDStallingsV. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastr Nutr. 2002;35:246-259.
6.
GottschlichMM. The A.S.P.E.N. Nutrition Support Core Curriculum: A Case-Based Approach—The Adult Patient. Silver Spring, MD: American Society for Parenteral and Enteral Nutrition; 2007.
7.
DavisPB. Cystic fibrosis since 1938. Am J Respir Crit Care Med. 2006;173(5):475-482.
8.
FiekerAPhilpottJArmandM. Enzyme replacement therapy for pancreatic insufficiency: present and future. Clin Exp Gastroenterol. 2011;4:55-73.
9.
Wouthyzen-BakkerMBodewesFAVerkadeHJ. Persistent fat malabsorption in cystic fibrosis: lessons for patient s and mice. J Cyst Fibros. 2011;10:150-158.
10.
PencharzPBDuriePR. Pathogenesis of malnutrition in CF. Clin Nutr. 2000;19(6):387-394.
11.
BradyMSGarsonJLKrugSK. An enteric-coated high-buffered pancreas lipase reduces steatorrhea in patients with cystic fibrosis: a prospective, randomized study. J Am Diet Assoc. 2006;106(8):1181-1196.
12.
KalninsDEllisLCoreyM. Enteric-coated pancreatic enzyme with bicarbonate is equal to standard enteric-coated enzyme in treating malabsorption in cystic fibrosis. J Pediatr Gastr Nutr. 2006;42(3):256-261.
13.
JonesA. Drug therapies for reducing gastric acidity in people with cystic fibrosis. Cochran Collab. 2003;2:1-16.
14.
BorowitzDGrandRJDuriePR. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. Consensus Committee. J Pediatr. November1995;127(5):681-684.
15.
FitzSimmonsSCBurkhartGABorowitzD. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med. 1997;336:1283-1289.
16.
SmythRL. Fibrosing colonopathy in cystic fibrosis. Arch Dis Child. 1996;74:464-468.
WilschanskiMDuriePR. Patterns of GI disease in adulthood associated with mutations in the CFTR gene. Gut. 2007;56:1153-1163.
19.
PerettiNMarcilVDrouinELevyE. Mechanism of lipid malabsorption in cystic fibrosis: the impact of essential fatty acid deficiency. Nutr Metab (Lond). 2005;2:11-29.
20.
CorbettKKelleherSRowlandM. Cystic fibrosis-associated liver disease: a population based study. J Pediatr. 2004;145:327-332.
21.
KellyAMoranA. Update on cystic fibrosis related diabetes. J Cyst Fibros. 2013;12(4):318-331.
22.
LangSHanseAThorsteinssonBNerupJKochC. Glucose tolerance in patients with cystic fibrosis: five year prospective study. BMJ. 1995;311:655-659.
23.
AustinAKalhanSCOrensteinDNixonPArslanianS. Roles of insulin resistance and beta-cell dysfunction in the pathogenesis of glucose intolerance in cystic fibrosis. J Clin Endocrinol Metab. 1994;79:80-85.
24.
O’RiordanSMRobinsonPDDonaghueKCMoranA. Management of cystic fibrosis-related diabetes. Pediatr Diabetes. 2008;9:338-344.
25.
HameedSMortonJRJaffeA. Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain. Diabetes Care. 2010;33:221-226.
26.
MoranAPekowPGroverP. Insulin therapy to improve BMI in cystic fibrosis-related diabetes therapy trial. Diabetes Care. 2009;32:1783-1788.
27.
HameedSMortonJRFieldPI. Once daily insulin detemir in cystic fibrosis with insulin deficiency. Arch Dis Child. 2012;97:464-467.
28.
BizzarriCLucidiVCiampaliniPBellaSRussoBCappaM. Clinical effects of early treatment with insulin glargine in patients with cystic fibrosis and impaired glucose tolerance. J Endocrinol Invest. 2006;29:RC1-4.
29.
MozzilloEFranzeseAValerioG. One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements. Pediatr Diabetes. 2009;10:162-167.
30.
ShepherdSLHovelMFHarwoodIRGrangerLDHofstetterCRMolgaardC. A comparative study of psychosocial assets of adults with cystic fibrosis and their healthy peers. Chest. 1990;97:1310-1016.
31.
CzyzewskiDIKoocherG. Medical compliance and coping with cystic fibrosis. J Child Psychol Psych. 1987;28:311-319.
32.
HammonsAKFieseB. Mealtime interactions in families of a child with cystic fibrosis: A meta-analysis. J Cyst Fibros. 2010;9:377-384.
33.
StarkLJOpipariLCSpiethLE. Contribution of behavior therapy in dietary treatment of cystic fibrosis: a randomized controlled study with 2-year follow up. Behav Ther. 2003;34:237-258.
34.
QuitnnerALTolbertVERegoliMJOrensteinDHollingsworthJLEigenH. Development of the role- play inventory of situations and coping strategies for parents of children with cystic fibrosis. J Pediatr Psychol. 1996;21:209-235.
35.
StarkLJJelalianEPowersSW. Parent and child mealtime behaviors in families of children with cystic fibrosis. J Pediatr. 2000;136:195-200.
36.
GoodwinB. Nutrition issues in cystic fibrosis. Pract Gastroenterol. 2005;27:76-94.
FiekerAPhilpottJArmandM. Enzyme replacement therapy for pancreatic insufficiency: present and future. Clin Exp Gas. 2011;4:55-73.
39.
O’BrienCEHardenHComG. A survey of nutrition practices for patients with cystic fibrosis. Nutr Clin Pract. 2013;28:237-241.
40.
ErskineJMLingardCSontagM. Update on enteral nutrition support for cystic fibrosis. Nutr Clin Pract. 2007;22:223-232.
41.
MichelSHMaqboolAHannaMDMascarenhasM. Nutrition management of pediatric patients who have cystic fibrosis. Pediatr Clin N Am. 2009;56:1123-1141.
42.
BradleyGMCarsonKALeonardARMogayzelPJOliva-HemkerM. Nutritional outcomes following gastrostomy in children with cystic fibrosis. Pediatr Pulm. 2012;47(8):473-478.
43.
TrabulsiJIttenbachRFSchallJI. Evaluation of formulas for calculating total energy requirements of preadolescent children with cystic fibrosis. Am J Clin Nutr. 2007;85:144-151.
44.
GelfondDBorowitzD. Gastrointestinal complications of cystic fibrosis. Clin Gastroenterol Hepatol. 2013;11:333-343.
45.
BorowitzDDuriePRClarkeLL. Gastrointestional outcomes and confounders in cystic fibrosis. J Pediatr Gastr Nutr. 2005;41:273-285.
46.
FridgeJLConradCGersonLCastilloROCoxK. Risk factors for small bowel bacterial overgrowth in Cystic Fibrosis. JPGN. 2007;44:212-218.
47.
HouwenRHvan der DoefHPSermetI. Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristic and treatment of DIOS. J Pediatr Gastr Nutr. 2009;49:54-58.
48.
GoralskiJLLercherDMDavisSDDellonES. Eosinophilic esophagitis in cystic fibrosis: a case series and review of literature. J Cystic Fibrosis. 2012;12:9-14.
49.
NasrSZDruryD. Appetite stimulants use in cystic fibrosis. Pediatr Pulmonol. 2008;43:209-219.
50.
PowersSWPattonSRHenryRHeidemannMStarkLJ. A tool to individualize nutrition care for children with cystic fibrosis: reliability, validity, and utility of the CF individualized nutritional assessment of kids eating. Child Health Care. 2005;32:113-131.
51.
ShepherdRWHoltTLVasques-VelasquezLCowardWAPrenticeALucasA. Increased energy expenditure in young children with cystic fibrosis. Lancet. 1988;1:1300-1303.
52.
FriedMDDuriePRTsuiLCCoreyMLevisonHPencharzPB. The cystic fibrosis gene and resting energy expenditure. J Pediatr. 1991;199:913-916.
53.
GirardetJPTounianPSardetA. Resting energy expenditure in infants with cystic fibrosis. J Pediatr Gastroenterol Nutr. 1994;18:214-219.
54.
TomezkoJLStallingsVAKawchakDAGoinJEDiamondGScanlinTF. Energy expenditure and genotype in children with cystic fibrosis. Pediatr Res. 1994;35:451-460.
55.
ZemelBSKawchakDACnannAZhaoHScanlinTFStallingsVA. Prospective evaluation of resting energy expenditure, nutritional status, pulmonary function and genotype in children with cystic fibrosis. Pediatr Res. 1996;40:578-586.
56.
AllenJRMcCauleyJCSelbyAM. Differences in resting energy expenditure between male and female children with cystic fibrosis. J Pediatr. 2003;142:15-19.
57.
MoudiouTGalli-TsinopoulouANousia-ArvanitakisS. Effect of exocrine pancreatic function on resting energy expenditure in cystic fibrosis. Acta Paediatrica. 2007;96:1521-1525.
58.
BarclayAAllenJRBlylerE. Resting energy expenditure in females with cystic fibrosis-is it affected by puberty?Eur J Clin Nutr. 2007;61:1207-1212.
59.
GrungowJAzcueMBerallGPencharzP. Energy expenditure in cystic fibrosis during activities of daily living. J Pediatr. 1992;122:243-246.
60.
BarrySGallagherC. Corticosteroids and skeletal muscle function in cystic fibrosis. J Appl Physiol. 2003;95:1379-1384.
61.
ThomsonMAWilmottRWWainwrightCMastersBFrancisPJShepherdRW. Resting energy expenditure, pulmonary inflammation, and genotype in the early course of cystic fibrosis. J Pediatr. 1996;129:367-373.
62.
DivangahiMBalghiHDanialouG. Lack of CFTR in skeletal muscle predisposes to muscle wasting and diaphragm muscle pump failure in cystic fibrosis mice. PLoS Genet. 2009;5:e1000586.
63.
StephensonALMannikLAWalshS. Longitudinal trends in nutritional status and the relation between lung function and BMI in cystic fibrosis: a population-based cohort study. Am J Clin Nutr. 2013;97:872-877.
64.
StallingsVAFungEBHofleyPMScanlinTF. Acute pulmonary exacerbation is not associated with increased energy expenditure in children with cystic fibrosis. J Pediatr. 1998;132:493-499.
65.
NaonHHackSSheltonMTGotthofferRCGozalD. Resting energy expenditure. Evolution during antibiotic treatment for pulmonary exacerbations in cystic fibrosis. Chest. 1993;103:1819-1825.
66.
ShepherdRWHoltTLCleghornGWardLCIslesAFrancisP. Short-term nutritional supplementation during management of pulmonary exacerbations in cystic fibrosis: a controlled study, including effects of protein turnover. Am J Clin Nutr. 1988;48:235-239.
RhodesBNashEFTullisE. Prevalence of dyslipidemia in adults with cystic fibrosis. J Cyst Fibros. 2010;9:24-28.
69.
DavisPBYasothanUKirkpatrickP. Ivacaftor. Nature Rev Drug Disc. 2012;11(5):349-350.
70.
DaviesJCWainrightCECannyGJ. Efficacy and safety of Ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med. 2013;187(11):1219-1225.
